Literature DB >> 12545034

A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).

Donald B Chalfin, Daniel Teres, John Rapoport.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12545034     DOI： 10.1097/00003246-200301000-00049

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  4 in total

1.  An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.

Authors:  Michael A Fischer; Craig M Lilly; William W Churchill; Lindsey R Baden; Jerry Avorn
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Authors:  James E Frampton; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  Evidence-based medicine: classifying the evidence from clinical trials--the need to consider other dimensions.

Authors:  Rinaldo Bellomo; Sean M Bagshaw
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

4.  The need to reform our assessment of evidence from clinical trials: a commentary.

Authors:  Sean M Bagshaw; Rinaldo Bellomo
Journal:  Philos Ethics Humanit Med       Date:  2008-09-30       Impact factor: 2.464
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.